Logo image of VTGN

VISTAGEN THERAPEUTICS INC (VTGN) Stock Fundamental Analysis

NASDAQ:VTGN - US92840H4002 - Common Stock

3.17 USD
+0.11 (+3.59%)
Last: 8/22/2025, 8:00:02 PM
3.23 USD
+0.06 (+1.89%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

3

Overall VTGN gets a fundamental rating of 3 out of 10. We evaluated VTGN against 549 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VTGN as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, VTGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VTGN had negative earnings in the past year.
In the past year VTGN has reported a negative cash flow from operations.
VTGN had negative earnings in each of the past 5 years.
VTGN had a negative operating cash flow in each of the past 5 years.
VTGN Yearly Net Income VS EBIT VS OCF VS FCFVTGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

VTGN has a Return On Assets (-51.25%) which is in line with its industry peers.
VTGN has a Return On Equity of -58.31%. This is in the better half of the industry: VTGN outperforms 61.02% of its industry peers.
Industry RankSector Rank
ROA -51.25%
ROE -58.31%
ROIC N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
VTGN Yearly ROA, ROE, ROICVTGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VTGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTGN Yearly Profit, Operating, Gross MarginsVTGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K -10K 20K

More info and screens

7

2. Health

2.1 Basic Checks

VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTGN has been increased compared to 1 year ago.
VTGN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VTGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VTGN Yearly Shares OutstandingVTGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
VTGN Yearly Total Debt VS Total AssetsVTGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

VTGN has an Altman-Z score of -1.91. This is a bad value and indicates that VTGN is not financially healthy and even has some risk of bankruptcy.
VTGN has a Altman-Z score (-1.91) which is in line with its industry peers.
There is no outstanding debt for VTGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.91
ROIC/WACCN/A
WACC9.76%
VTGN Yearly LT Debt VS Equity VS FCFVTGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

VTGN has a Current Ratio of 9.35. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.35, VTGN is doing good in the industry, outperforming 79.05% of the companies in the same industry.
A Quick Ratio of 9.35 indicates that VTGN has no problem at all paying its short term obligations.
VTGN's Quick ratio of 9.35 is fine compared to the rest of the industry. VTGN outperforms 79.23% of its industry peers.
Industry RankSector Rank
Current Ratio 9.35
Quick Ratio 9.35
VTGN Yearly Current Assets VS Current LiabilitesVTGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VTGN have decreased strongly by -20.41% in the last year.
VTGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.32%.
VTGN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.07% yearly.
EPS 1Y (TTM)-20.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.29%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%190.48%

3.2 Future

The Earnings Per Share is expected to grow by 37.40% on average over the next years. This is a very strong growth
Based on estimates for the next years, VTGN will show a very strong growth in Revenue. The Revenue will grow by 235.72% on average per year.
EPS Next Y-4.33%
EPS Next 2Y-4.62%
EPS Next 3Y16.91%
EPS Next 5Y37.4%
Revenue Next Year-16.94%
Revenue Next 2Y151.31%
Revenue Next 3Y359.06%
Revenue Next 5Y235.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTGN Yearly Revenue VS EstimatesVTGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 200M 400M 600M 800M 1B
VTGN Yearly EPS VS EstimatesVTGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VTGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTGN Price Earnings VS Forward Price EarningsVTGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTGN Per share dataVTGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as VTGN's earnings are expected to grow with 16.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.62%
EPS Next 3Y16.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VISTAGEN THERAPEUTICS INC

NASDAQ:VTGN (8/22/2025, 8:00:02 PM)

After market: 3.23 +0.06 (+1.89%)

3.17

+0.11 (+3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05
Inst Owners51.6%
Inst Owner Change-3.47%
Ins Owners0.34%
Ins Owner Change10.12%
Market Cap94.66M
Analysts88
Price Target13.26 (318.3%)
Short Float %1.64%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3%
Min EPS beat(2)-5.58%
Max EPS beat(2)11.57%
EPS beat(4)3
Avg EPS beat(4)13.41%
Min EPS beat(4)-5.58%
Max EPS beat(4)32.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.89%
Min Revenue beat(2)-19.67%
Max Revenue beat(2)27.45%
Revenue beat(4)1
Avg Revenue beat(4)-17.38%
Min Revenue beat(4)-72.55%
Max Revenue beat(4)27.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)37.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 135.55
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS0.02
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.25%
ROE -58.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.26%
Cap/Sales 18.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.35
Quick Ratio 9.35
Altman-Z -1.91
F-Score2
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)67.45%
Cap/Depr(5y)113.81%
Cap/Sales(3y)45.45%
Cap/Sales(5y)36.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.29%
EPS Next Y-4.33%
EPS Next 2Y-4.62%
EPS Next 3Y16.91%
EPS Next 5Y37.4%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%190.48%
Revenue Next Year-16.94%
Revenue Next 2Y151.31%
Revenue Next 3Y359.06%
Revenue Next 5Y235.72%
EBIT growth 1Y-55.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.34%
OCF growth 3YN/A
OCF growth 5YN/A